Oncotarget Editorial Board Members win 2019 Nobel Prize
Oncotarget Editorial Board Members win 2019 Nobel Prize
NEW YORK, Oct. 15, 2019 /PRNewswire/ -- The 2019 Nobel Prize in Physiology or Medicine has been awarded jointly to Oncotarget Editorial Board Members William G. Kaelin Jr., and Gregg L. Semenza for their discoveries of "how cells sense and adapt to oxygen availability." The pair was named alongside UK physician-scientist Sir Peter J. Ratcliffe.
The Nobel Committee made the announcement in Stockholm on Monday, October 7th and the discoveries have implications for how we understand and potentially treat a range of conditions like cancer, heart attack, stroke and anemia.
Both William G. Kaelin and Gregg L. Semenza are founding members of Oncotarget, launched in 2010. Oncotarget is a weekly peer-reviewed open access bio-medical journal covering research on all aspects of oncology. The editors-in-chief are Mikhail (Misha) Blagosklonny and Andrei V. Gudkov.
Dr. Gudkov comes to Roswell Park from the Lerner Research Institute, Cleveland Clinic Foundation where he served as chair of the Department of Molecular Genetics and professor of biochemistry at Case Western University. He earned his doctoral degree in Experimental Oncology at the Cancer Research Center and a Doctorate of Science (D.Sci) in Molecular Biology at the Moscow State University, Russia. He has authored or co-authored over 200 scientific articles and holds more than 30 patents.
Dr. Blagosklonny earned both his MD in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg, Russia. Dr. Blagosklonny subsequently relocated to the United States, where he was awarded the prestigious Fogarty Fellowship from the National Institutes of Health and worked several years at the National Cancer Institute, Bethesda, MD. Later he held a few positions before he was appointed Professor of Oncology at Roswell Park Cancer Institute in 2009. Dr. Blagosklonny is the author of over 200 articles. Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.
Gregg L. Semenza has published eight papers in Oncotarget.
Oncotarget is well known for publishing papers from Nobel prize-winning scientists. Andrew Schally, another Nobel prize winner, and also a member of the Editorial Board of Oncotarget, has published 12 papers in Oncotarget.
During the relatively short history of Oncotarget, many members of the Editorial Board have become members of the National Academy of Sciences USA and have won Nobel, Lasker and other prestigious prizes and awards.
Media Contact:
media@oncotarget.com
716-4494773
Oncotarget.com
SOURCE Oncotarget
Related Links
When public speak of modern medicine, accuracy plays one of the most important roles and people’s lives are directly dependent on it. Hence, any researches related to medicine are required to comply with the highest standards. The problem today is that any conclusions of researches can be posted online and used as a reference without being adequately checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this issue and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The major principle of this journal is based on Altmetric scores that are used as a quality measure. That helps both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with corresponding scores higher than 100 as well as reports mentioned above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the necessary help to anybody, who has interest in oncology.
Zoya Demidenko
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was published back in 2018 by Oncotarget and completed by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The publication has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are aiming to understand the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Likewise, the publication about melanoma, was utilized for citations in different news articles 69 times. Besides that, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This research has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive helpful scientific facts. Oncotarget is glad to have the chance to share with online viewers this highly appreciated and high-quality information, that is trustworthy and reliable.
https://scholar.google.com/citations?user=REO9YogAAAAJ&hl=en
Comments
Post a Comment